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Introduction: The neuropsychological battery of the Uniform Data Set
(UDSNB) was implemented in 2005 by the National Institute on Aging
(NIA) Alzheimer Disease Centers program to measure cognitive per-
formance in dementia and mild cognitive impairment due to Alzheimer
Disease. This paper describes a revision, the UDSNB 3.0.
Methods: The NeuropsychologyWork Group of the NIA Clinical Task
Force recommended revisions through a process of due diligence
to address shortcomings of the original battery. The UDSNB 3.0 covers
episodic memory, processing speed, executive function, language, and
constructional ability. Data from 3602 cognitively normal participants
in the National Alzheimer Coordinating Center database were analyzed.
Results: Descriptive statistics are presented. Multivariable linear
regression analyses demonstrated score differences by age, sex, and
education and were also used to create a normative calculator
available online.
Discussion: The UDSNB 3.0 neuropsychological battery provides a
valuable non proprietary resource for conducting research on cog-
nitive aging and dementia.
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Since 2005, the University of Washington’s NationalAlzheimer’s Coordinating Center (NACC) has collected
the Uniform Data Set (UDS) on participants from over 30
past and present US Alzheimer’s Disease Centers (ADC).
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The UDS consists of data collection protocols used sys-
tematically on participants enrolled into the Clinical Cores
of each ADC.1,2 Participants with clinical diagnoses of
normal cognition (NC), mild cognitive impairment (MCI)
and dementia of various etiologies including Alzheimer
disease (AD) are recruited, enrolled, and followed annually.
Consent is obtained at the individual ADCs, as approved by
individual Institutional Review Boards (IRBs), and the
University of Washington’s IRB has approved the sharing
of deidentiﬁed UDS data. The UDS data, include demo-
graphics, medical history, medication use, clinical and
neurological examination ﬁndings, measures of function and
behavior, clinical ratings of dementia severity [eg, clinical
dementia rating (CDR)3], and neuropsychological test
scores. Systematic guidelines for clinical diagnosis are based
on the most up to date published diagnostic research
criteria.1,4
All UDS data collection instruments were constructed
with the guidance and approval of the Clinical Task Force
(CTF), a group originally constituted by the National
Institute on Aging (NIA) to develop standardized methods
for collecting longitudinal data that would encourage and
support collaboration across the ADCs.1,5 As of December
1, 2016, the NACC database contained data on 34,748 UDS
participants from past and present ADCs.
ADCs used the ﬁrst version of the UDSNB starting in
September 2005, and in February 2008, a second version,
UDSNB 2.0, was implemented with slight revisions to
instructions and data collection forms. Tests in the original
version of the battery, used until March 2015, were chosen
to capture the continuum of cognitive decline from NC
through AD dementia, incorporating relevant domains
described in detail previously.2 An online calculator was
developed to aid in scoring.6
In 2010, encouraged by recognition of the growing
importance of diagnostic biomarkers7 and the identiﬁcation
of preclinical stages of AD,8 the Neuropsychology Work
Group, a committee to review the UDSNB 2.0 and make
recommendations for future data collection, was convened.
This paper describes the rationale and procedures for the
development of UDSNB 3.0 and provides normative test
scores for a cohort of cognitively normal individuals from
the NACC database.
METHODS
Rationale and Procedures for Battery Design and
Test Selection
The CTF and Neuropsychology Work Group outlined
the rationale for change. First, in longitudinal follow-up,
healthy controls showed practice effects, especially for the
memory task, even reciting the story before administration
on visits subsequent to baseline. UDSNB 2.0 measures were
published tests, increasing the potential for multiple expo-
sures either through clinical practice or in ancillary research
conducted at the ADCs. Licensing costs and restrictions on
sharing these instruments with intramural, extramural, and
international researchers also created challenges for collab-
oration. Furthermore, the importance of early detection
required instruments that would be sensitive to earlier stages
of cognitive decline or even “preclinical” states. Finally,
UDSNB 2.0 lacked tests of visuospatial functions and
nonverbal memory, both of which can constitute areas of
early decline, particularly in those with Lewy body
disease9,10 or those with the posterior cortical atrophy var-
iant of AD.11–13 Therefore, we created novel tests to address
some of the shortcomings of the existing battery, while at
the same time having a mechanism for preserving longi-
tudinal continuity with previous data.
The Work Group included members from several
ADCs to ensure multicenter representation, and exofﬁcio
members from the NACC and the NIA. The group con-
ducted weekly or monthly conference calls, as needed, and
in-person meetings 1 to 2 times per year to outline a strategy
to assess options for change. This included considering dif-
ferent platforms for testing (paper-and-pencil vs. computer),
considering whether or not to change the types of constructs
tested with the UDSNB 3.0, and evaluating existing
instruments for inclusion into the new battery. Criteria
were developed to aid in decision-making. Early on, after
reviewing a library of potential tests, the group decided to
adopt nonproprietary measures to allow the ADCs to freely
share the battery with collaborators. Moreover, early on, it
was decided to postpone computerized testing, as the ﬁeld was
rapidly evolving with increasingly sophisticated technology.
The UDSNB 2.0 faced the serious issue of a new bat-
tery disrupting the longitudinal follow-up of participants
tested with the initial battery since 2008. Therefore, the
decision was made after careful review by the Work Group
and the CTF and presentations to the centers, to model the
new battery on the old one and to drop or replace existing
measures. Digit Symbol from the WAIS-R was dropped,
whereas the trail making tests and category list generation
tests (animals, fruits, and vegetables) were retained. In
addition, 4 measures were replaced with similar measures
developed previously by several of the centers and tested in
published research studies. The section below describes the
instruments.
Materials, data recording forms, and a manual for
administration and scoring were created and revised with
feedback from the centers. After a brief period of pilot data
collection with the new instruments to reﬁne the instructions
and address any questions about administration and scoring
we made additional revisions and conducted a larger pilot
study (N= 935) that compared the UDSNB 2.0 and 3.0
versions in individuals divided into 4 groups based on their
Mini Mental State Examination (MMSE)14 scores (26 to 30,
21 to 25, 16 to 20, 10 to 15) in a “crosswalk” study.15 The
pairs of scores for the original and corresponding replace-
ment tests were compared using equipercentile equating,
and the analyses provided a crosswalk of equivalent test
scores between the original and replacement tests [eg, a
score of 15 on the Montreal Cognitive Assessment (MoCA)
is equivalent to a score of 21 on the MMSE]. The results of
the crosswalk study provided good evidence for relatively
reliable equivalence across both measures and that the
chosen tests were reasonable replacements for the older tests.
Crosswalk scores could also assist in making longitudinal
comparisons.
Selection of Tests for the UDS
Neuropsychological Battery 3.0
The Work Group recommended replacing the MMSE
with the MoCA,16,17 Logical Memory18 immediate and
delayed with the Craft Story 21 immediate and delayed
recall19; digit span forward and backward with the number
span forward and backward test; and the Boston naming test
(BNT) with the multilingual naming test (MINT).20 Each
decision was based on the rationale outlined below.
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General Cognitive Measure
The MoCA16,17 was selected to replace the MMSE as a
measure of overall cognitive impairment. Factors inﬂuenc-
ing this decision included the fact that the MOCA is more
difﬁcult than the MMSE as demonstrated in studies showing
lower MoCA than MMSE scores in the same samples21 and,
hence, more likely to detect subtle cognitive deﬁcits. Fur-
thermore, ﬂoor and ceiling effects are less common with the
MoCA, which also allows for a broader range of scores in
MCI samples than does the MMSE.22 Therefore, the MoCA
is more appropriate than the MMSE for detecting early
cognitive decline. The MoCA has been validated in white23
and African American24 groups. A disadvantage of the
MoCA is that it can yield lower scores in diverse healthy
population-based samples.25 However, an abbreviated ver-
sion reportedly demonstrated predictive ability with respect
to diagnosis of MCI in a low-education, illiterate sample.26
In another study, MoCA was more sensitive to MCI and
discriminated MCI from other samples better than the
MMSE.27,28 MoCA scores have also been shown to corre-
late with the Activities of Daily Living Questionnaire29 a
measure of functional integrity in dementia.30 The MoCA
has the further advantage of yielding not only a total score
(overall measure) but also index scores based on individual
items tapping domains of attention, retentive memory, ori-
entation, language, and executive function.31
The MoCA requires about 10 minutes to administer
and yields a total score of 30 and the above-mentioned
domain index scores. The index scores (not included in the
present report) offer the potential to identify early dementia
proﬁles of clinical dementia subtypes such as behavioral
variant frontotemporal dementia and primary progressive
aphasia. The memory index score has been shown to be
especially predictive of decline from amnestic MCI to AD
dementia.31 The paper-and-pencil version of the MoCA has
been translated into multiple languages and dialects within
languages32 and is freely available (www.mocatest.org/).
The NACC was given permission to use it for 25 years





Memory loss is the hallmark symptom of the most
common clinical dementia syndrome associated with AD.33
Early studies of AD dementia emphasized the importance of
measures of episodic memory, such as word list learning and
story recall, in the evaluation for dementia. The group had
decided on a story memory test, as most ADCs were already
using LogicalMemory, immediate, and delayed recall conditions.
Craft and colleagues had designed multiple forms of a
story recall test similar to Logical Memory in a study of the
impact of insulin on cognition in mild AD dementia.19,34
The complete set of 22 stories had previously been tested for
equivalence in a diverse sample of college age adults who
were administered all of the stories in counter balanced
order in the laboratory of Andrew Saykin (personal oral
communication) and provided to the Work Group for
consideration. Additional data on alternate sets of stories
were included in published studies of patients undergoing
systemic chemotherapy for treatment of breast cancer as
well as individuals with traumatic brain injury and healthy
controls.35–38 In a pilot study to determine the equivalence
of 22 stories in middle-aged and older adults the Work
Group determined that 3 stories offered the greatest rela-
tionship to Logical Memory and to one another. These 3
were reviewed by the work group and 1 was chosen for its
content relevance to a diverse population, “Craft Story 21.”
Scoring of Logical Memory allows several acceptable
responses for each item recalled. Following the protocol
from Craft et al,34 items were scored in a similar manner to
Logical Memory (paraphrase score) but another score was
also calculated (verbatim score), allocating a point for each
item recalled exactly as delivered in the story. The verbatim
score (not included in the present report) was intended to
serve as potentially more sensitive than the paraphrase score
in detecting very early memory decline.
Finally, we introduced a novel measure of nonverbal
memory, a function not previously included in the UDSNB
2.0. Following the copy of the Benson complex39 ﬁgure (see
the Visuospatial Test section) delayed ﬁgure reproduction
was tested.
Language Tests
The 32-item MINT20,40 was selected to replace the
short BNT. The MINT was originally developed to test
naming in 4 languages, English, Spanish, Hebrew, and
Mandarin Chinese, taking care to equate the level of difﬁ-
culty of items across languages. The BNT was developed in
New England and designed for American English speakers
and contains items that either have no equivalent word or
different frequencies of usage in other languages. The
MINT is sensitive to naming impairment in AD.20
Word ﬂuency is measured with semantic and letter word
list generation tests. The former were part of UDSNB 2.0,
whereas 2 letter generation tasks were added (“F” and “L”)
for UDSNB 3.0. Each task requires 60 seconds and correct
items are totaled. Note is made of errors and rule violations.
Visuospatial Tests
The UDSNB 2.0 did not contain a visuospatial test.
Visuospatial symptoms emerge in later stages of amnestic
dementia due to AD but also may appear early in the
clinical syndromes of posterior cortical atrophy and
dementia associated with cortical Lewy body disease. The
Benson complex ﬁgure39 was added as a test of construc-
tional ability (Copy condition). Figural elements are scored
for presence and placement. Reproduction is tested after a
delay to measure retentive memory (see the Episodic
Memory section). Comparison between patients with clin-
ical dementia of the Alzheimer type and frontotemporal
dementia showed distinctive proﬁles of performance and
associations with frontal and parietal cortical atrophy
regions in the groups.39,41
Immediate Attention, Working Memory, Executive
Attention Tests
Immediate attention span is commonly tested with
Digit Span.18 For studies requiring multiple forms to reduce
practice effects, a series of number sets was randomly gen-
erated to provide alternatives to the digit span test (Joel
Kramer lab, personal oral communication). The number
spans for the UDS task were randomly generated with the
restriction that no digit would be adjacent to a digit that was
one higher or one lower (eg, a “7” would not be succeeded
or preceded by a 6 or 8). Every attempt was also made to
exclude sequences that contained area codes. The number
span is the longest list recalled. The total number of trials
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administered up to failure on 2 trials at 1 length is also
recorded. Backward span is a measure of working memory.
The trail making tests were retained from the UDSNB 2.0 to
measure processing speed (part A) and executive attention
(part B).
Study Sample
This report is based on analyses of UDS data submitted
to NACC by the ADCs between March 15, 2015 and
November 30, 2016. The sample was restricted to individuals
who received the UDSNB 3.0 and at that visit had a clinical
diagnosis of NC and a global CDR score of 0. If a participant
had received UDSNB 3.0 more than once, data were included
from only the ﬁrst administration. Although some partic-
ipants’ scores on the UDSNB 3.0 seemed to be outside the
range of normal scores (eg, MoCA score of 9), we chose not
to remove any participants from the descriptive analyses
because normalcy was not deﬁned by the tests. Therefore,
we describe the full range of scores in those with a clinical
diagnosis of NC and a global CDR= 0.
Data, Analyses, Normative Calculator
First we describe the demographics of the sample (age,
education, and sex).The mean, median, 25th and 75th per-
centiles, and ranges of scores for the overall sample are pre-
sented. Histograms are provided for each of the tests to
illustrate the distribution of scores in the overall sample. The
mean scores and SDs for each test are provided by age divided
into 5 groups (< 60, 60 to 69, 70 to 79, 80 to 89, ≥ 90 y) and
education, divided into 4 groups (≤ 12, 13 to 15, 16, ≥ 17 y).
Unadjusted linear regression analyses tested for differences by
age or education group. Finally, we ran linear regression
models to estimate the effect of age (continuous), sex, and
education (continuous) on each neuropsychological measure.
Adjusted linear regression models were ﬁrst run with either
age, sex, or education predicting the neuropsychological test
score (data not shown), and then multivariable models were
run with all 3 demographics included in the model.
We developed a calculator for the UDSNB 3.0 tests
based on previously published methods used to produce the
calculator for UDSNB 2.0 tests.6 Although our descriptive
analyses focused on all participants meeting our eligibility
criteria, for the normative calculator, we excluded a handful
of participants who performed 5 SDs outside of the mean on
any particular test to improve the distribution of residuals and
better satisfy model assumptions. This restriction resulted in
excluding the following participants from the regression
analyses: 5 participants from the analysis of the MoCA, 4
participants from the analysis of the Benson complex ﬁgure
copy, 16 participants from the analysis of the trail making
part A, and 5 participants from the analysis of the MINT.
RESULTS
The sample included 3602 cognitively normal partic-
ipants over age 60 receiving the UDSNB 3.0 (Table 1). The
majority of the sample (65%) were women and were between
70 and 89 years of age (67%) and highly educated (69%).
These analyses did not divide the sample by race, as most
participants in the sample were white (83%), with an addi-
tional 14% African American, and 3% other race, reﬂecting
the overall distribution of these groups within the ADCs
receiving the UDS.
Means, 25th, 50th, and 75th percentile, and score
ranges for each test in the overall sample are reported in
Table 2. Histograms demonstrate whether the distribution
of test scores were approximately normal (Fig. 1). Tests with
an approximately normal distribution of scores included
Craft Story immediate and delayed (paraphrase and ver-
batim), number span forward and backward (total correct
trials and longest span), the letter list generation task (F-
words and L-words), and the Benson complex ﬁgure recall.
Scores on the MoCA, MINT, and copy condition of the
Benson complex ﬁgure copy were highly skewed due to
ceiling effects. However, the MoCA seems to be less affected
by ceiling effects than the MMSE.2
Table 3 shows the means and SDs by each measure
across the 5 age groups, and Table 4 shows means and SDs
for the 4 education groups. In the multivariable regres-
sion analyses (Table 5), women performed statistically
signiﬁcantly (P< 0.01) better than men on the Craft story
immediate and delayed, verbal ﬂuency phonemic test,
and vegetables list generation, but worse on the Benson
copy ﬁgure recall, number span forward, and MINT
(Table 5). Women and men performed similarly, without
statistically signiﬁcant differences, on the Benson com-
plex ﬁgure copy, number span backward, animal list
generation, and trail making parts A and B. Increasing
age was associated with worse scores and increasing years
of education was associated with better scores on all of
the tests (P< 0.01).
For the data to be useful in characterizing research
participants, a calculator was created to indicate the level
of performance on each measure. The calculator uses the
intercepts, regression coefﬁcients, and root mean square
errors resulting from the regression analyses described
above to calculate unadjusted and adjusted Z-scores for
individuals of a particular sex, age, and/or education level.
The root mean square error is the square root of the
TABLE 1. Sample Distribution by Sex, Age, and Education
Age (y) Education Male Female Total
< 60 ≤ 12 13 23 36
13-15 23 48 71
16 34 69 103
17+ 44 76 120
Missing 6 6 12
60-69 ≤ 12 32 65 97
13-15 47 142 189
16 102 164 266
17+ 158 293 451
Missing 3 7 10
70-79 ≤ 12 45 130 175
13-15 61 159 220
16 110 201 311
17+ 274 407 681
Missing 1 7 8
80-89 ≤ 12 27 77 104
13-15 26 103 129
16 59 112 171
17+ 151 177 328
Missing 1 1 2
≥ 90 ≤ 12 4 27 31
13-15 6 11 17
16 10 15 25
17+ 19 26 45
Missing 0 0 0
Grand total 1256 2346 3602
As of December 2016.
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TABLE 2. Summary Statistics for Clinically Cognitively Normal UDS Participants
Sample’s Scores
UDS Version 3 Neuropsychological Test* Domain Maximum Score N Mean (SD) Q25, Q50, Q75 Range
MoCA, total score Dementia severity 30 3581 26.3 (2.8) 25, 27, 28 9-30
Craft Story 21 recall immed. verbatim, total units Memory 44 3552 21.9 (6.6) 17, 22, 27 0-38
Craft Story 21 recall immed. paraphrase, total units Memory 25 3552 16.1 (4.1) 14, 17, 19 0-25
Craft Story 21 recall delay. verbatim, total units Memory 44 3550 19.1 (6.7) 14, 19, 24 0-40
Craft Story 21 recall delay. Paraphrase, total units Memory 25 3550 15.1 (4.3) 12, 16, 18 0-25
Benson complex ﬁgure copy, total score Visuospatial 17 3584 15.6 (1.4) 15, 16, 17 0-17
Benson complex ﬁgure recall, total score Visuospatial/Memory 17 3576 11.2 (3.1) 9, 12, 13 0-17
Number span test forward, total correct trials Attention 14 3591 8.3 (2.3) 7, 8, 10 2-14
Number span test forward, longest span Attention 9 3591 6.7 (1.3) 6, 7, 8 3-9
Number span test backward, total correct trials Attention 14 3590 7.2 (2.2) 6, 7, 9 0-14
Number span test backward, longest span Attention 8 3590 5.1 (1.3) 4, 5, 6 0-8
MINT, total score Lang. naming 32 3564 30.0 (2.4) 29, 31, 32 0-32
Phonemic test, F-words total in 60 s Lang. verbal ﬂuency 40 3589 15.1 (4.7) 12, 15, 18 1-35
Phonemic test, L words total in 60 s Lang. verbal ﬂuency 40 3574 14.2 (4.5) 11, 14, 17 0-35
Phonemic test, total F-words and L-words Lang. verbal ﬂuency 80 3572 29.2 (8.6) 23, 29, 35 1-64
Animals list generation, total in 60 s Lang. category ﬂuency 77 3596 21.4 (5.7) 17, 21, 25 0-49
Vegetables list generation, total in 60 s Lang. category ﬂuency 77 3590 15.1 (4.3) 12, 15, 18 1-35
Trail making test part A, time (s) Processing speed 150 3583 30.9 (13.4) 22, 28, 36 9-150
Trail making test part B, time (s) Executive function 300 3561 82.2 (46.3) 54, 70, 95 13-300
As of December 2016.
*Higher scores indicate better scores except for the trail making test parts A and B.
Delay indicates delayed; Immed, immediate; Lang, language; Max, maximum; MINT, multilingual naming test; MoCA, Montreal Cognitive Assessment;
UDS, Uniform Data Set.
FIGURE 1. Histograms showing score distributions for each measure on the UDSNB 3.0. From these graphs, many of the measures have a
normal or near normal distribution, with the exception of theMoCA total score, the score for the copy of the Benson complex figure, and the total
score for the MINT. Immed. indicates immediate; MINT, multilingual naming test; MoCA, Montreal Cognitive Assessment; Paraph., paraphrase.
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average squared differences between the observed score
and the predicted score, which we substitute as an estimate
for a population SD. The adjusted Z-scores are calculated
for each test adjusting for a single demographic charac-
teristic (ie, sex, age, or education) and adjusting for all 3 of
these demographics. One can enter an individual’s demo-
graphics and raw test scores, and the calculator uses the
resulting Z-scores to calculate percentile estimates that
indicate the individual’s level of impairment on any given
test (eg, low average, or severely impaired). Two new
variables were also added to this calculator to improve the
precision of percentile estimates for trail making part A
and part B. These 2 tests are terminated if the subjects
cannot complete within a speciﬁed time length (150 s and
300 s for A and B, respectively), resulting in the same score
regardless of how many lines are correctly connected. We
added connections-per-second (correct lines connected
divided by the time to completion) for both Part A and B.
These 2 new variables provide more accurate Z-scores and
percentiles for the trail making tests.
TABLE 3. Mean Neuropsychological Test Scores by Age Group
Mean (SD)
UDS Version 3 Neuropsychological Test* < 60 y 60-69 y 70-79 y 80-89 y ≥ 90 y
Montreal Cognitive Assessment, total score 27.5 (2.1) 26.9 (2.4) 26.3 (2.7) 25.3 (3.0) 23.8 (3.5)
Craft Story 21 recall immed. verbat., total units 23.1 (6.8) 23.2 (6.4) 22.0 (6.5) 20.0 (6.6) 17.8 (6.4)
Craft Story 21 recall immed. paraph., total units 16.9 (4.1) 16.9 (3.9) 16.2 (4.0) 15.0 (4.2) 13.3 (4.4)
Craft Story 21 recall delay. verbat. total units 20.9 (7.0) 20.4 (6.4) 19.2 (6.6) 16.9 (6.6) 15.1 (5.8)
Craft Story 21 recall delay. paraph., total units 16.3 (4.4) 15.9 (4.0) 15.2 (4.1) 13.6 (4.5) 12.1 (4.3)
Benson complex ﬁgure copy, total score 15.7 (1.2) 15.8 (1.2) 15.6 (1.3) 15.4 (1.6) 15.5 (1.5)
Benson complex ﬁgure recall, total score 12.6 (2.4) 11.9 (2.8) 11.2 (3.0) 10.1 (3.3) 9.4 (3.6)
Number span test forward, total correct trials 8.7 (2.4) 8.4 (2.3) 8.3 (2.3) 8.0 (2.3) 7.6 (2.1)
Number span test forward, longest span 6.9 (1.3) 6.7 (1.3) 6.7 (1.3) 6.5 (1.3) 6.3 (1.3)
Number span test backward, total correct trials 7.8 (2.3) 7.4 (2.2) 7.1 (2.2) 6.8 (2.2) 6.4 (2.4)
Number span test backward, longest span 5.4 (1.3) 5.2 (1.3) 5.1 (1.3) 4.9 (1.3) 4.7 (1.4)
MINT, total score 30.1 (2.0) 30.3 (2.0) 30.1 (2.2) 29.6 (2.6) 28.4 (3.4)
Phonemic test, F-words total in 60 s 16.3 (4.4) 15.5 (4.6) 14.9 (4.7) 14.6 (4.8) 13.6 (5.0)
Phonemic test, L-words total in 60 s 15.3 (4.3) 14.8 (4.4) 14.0 (4.4) 13.7 (4.5) 12.5 (4.7)
Phonemic test, total F-words and L-words 31.3 (8.3) 30.0 (8.4) 28.8 (8.5) 28.2 (8.6) 26.1 (9.1)
Animals list generation, total in 60 s 23.6 (5.3) 22.7 (5.5) 21.2 (5.4) 19.5 (5.6) 17.0 (5.4)
Vegetables list generation, total in 60 s 16.3 (4.1) 16.0 (4.3) 15.0 (4.2) 14.0 (4.3) 12.4 (4.1)
Trail making test part A, time (s) 22.3 (8.4) 27.3 (9.6) 31.0 (10.8) 36.2 (13.3) 42.0 (14.3)
Trail making test part B, time (s) 55.4 (27.2) 70.1 (33.8) 82.7 (41.4) 102.0 (55.2) 140.6 (75.3)
*Higher scores indicate better scores except for the trail making test parts A and B; higher scores indicate slower time to completion.
Delay. indicates delayed; Immed, immediate; MINT, multilingual naming test; Paraph, paraphrase; UDS, Uniform Data Set; Verbat, verbatim.
TABLE 4. Mean Neuropsychological Test Scores by Education Group
Mean (SD)
UDS Version 3 Neuropsychological Test* ≤ 12 y 13-15 y 16 y 17+ y
MoCA, total score 24.1 (3.7) 25.7 (2.9) 26.6 (2.4) 26.9 (2.2)
Craft Story 21 recall immed. verbatim, total units 19.6 (7.1) 21.2 (6.5) 22.0 (6.5) 22.8 (6.4)
Craft Story 21 recall immed. paraphrase, total units 14.5 (4.7) 15.6 (4.0) 16.3 (4.1) 16.7 (3.8)
Craft Story 21 recall delay. verbatim, total units 16.6 (7.1) 18.3 (6.8) 19.2 (6.6) 20.0 (6.4)
Craft Story 21 recall delay. paraphrase, total units 13.2 (5.0) 14.4 (4.4) 15.3 (4.3) 15.8 (4.0)
Benson complex ﬁgure copy, total score 15.2 (1.5) 15.5 (1.4) 15.7 (1.3) 15.8 (1.2)
Benson complex ﬁgure recall, total score 10.2 (3.6) 11.0 (3.2) 11.4 (3.1) 11.5 (2.9)
Number span test forward, total correct trials 7.4 (2.2) 7.9 (2.2) 8.4 (2.2) 8.6 (2.3)
Number span test forward, longest span 6.2 (1.3) 6.5 (1.3) 6.8 (1.3) 6.9 (1.3)
Number span test backward, total correct trials 6.1 (2.3) 6.7 (2.2) 7.3 (2.2) 7.5 (2.2)
Number span test backward, longest span 4.5 (1.4) 4.9 (1.3) 5.2 (1.3) 5.3 (1.3)
MINT, total score 28.5 (2.9) 29.4 (2.4) 30.2 (2.0) 30.5 (2.0)
Phonemic test, F-words total in 60 s 12.8 (4.7) 13.9 (4.4) 15.2 (4.6) 16.1 (4.5)
Phonemic test, L-words total in 60 s 11.9 (4.5) 13.0 (4.4) 14.3 (4.1) 15.2 (4.3)
Phonemic test, total F-words and L-words 24.7 (8.6) 26.7 (8.3) 29.4 (8.1) 31.2 (8.2)
Animals list generation, total in 60 s 18.5 (5.4) 19.9 (5.3) 21.3 (5.1) 22.8 (5.7)
Vegetables list generation, total in 60 s 13.5 (4.0) 14.7 (4.0) 15.1 (4.1) 15.7 (4.5)
Trail making test part A, time (s) 35.1 (14.4) 32.1 (12.3) 29.7 (11.0) 29.2 (10.9)
Trail making test part B, time (s) 112.7 (69.8) 91.4 (51.5) 76.1 (36.4) 73.9 (35.9)
*Higher scores indicate better scores except for the trail making test parts A and B.
Delay. indicates delayed; Immed, immediate; MINT, multilingual naming test; MoCA, Montreal Cognitive Assessment; UDS, Uniform Data Set.
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DISCUSSION
This paper reports the results from a study to develop
normative data for the version 3.0 revision of the Uniform
Data Set Neuropsychological Battery. The complete UDS
contains not only the neuropsychological battery but also
demographic, medical, family history, neurological, bio-
marker, psychiatric, and functional data and available post
mortem diagnosis on Clinical Core participants who have
been followed longitudinally. Earlier versions have been
collected since 2005 and stored in the database of the NACC
at the University of Washington. All the data are available
for sharing with researchers and therefore provide a rich
source for generating hypotheses and investigating cognitive
aging and dementia in a well-deﬁned cohort.
The current revision of the neuropsychological bat-
tery provides an updated set of tests, targeting predom-
inantly the symptoms of the most typical, amnestic, pre-
sentation of AD. The tests are nonproprietary and have
the potential to increase sensitivity over former measures
to very early symptoms of cognitive decline in older
individuals with different levels of education. The new
measures are similar to the old measures but have also
enriched the standard data collection with novel scores to
enhance available data using a relatively brief battery. The
normative calculator provides a convenient tool to char-
acterize the level of performance on the measures of the




There are some limitations to the study reported above.
Although the ADCs encourage the participation of a diverse
sample with respect to sex, education, and race, there was an
overrepresentation of individuals who were white, female,
and highly educated. Therefore, the ﬁndings are most
relevant to research settings where these demographics are
representative of the research volunteers. It will be impor-
tant to expand the normative data for underrepresented
groups and also for population-based samples. Another
limitation is that the battery focuses on the spectrum from
healthy cognition to dementia of the Alzheimer type and
does not explicitly target symptoms associated with other
forms of dementia. The CTF has introduced additional data
collection modules, however, including specialized tests of
symptoms related to frontotemporal dementia. Plans are
under way to further expand clinical symptom assessment in
other dementia syndromes. The availability of the UDSNB
3.0 at no cost to researchers will aid in encouraging more
consistent and systematic data collection in disparate studies
of cognitive aging and dementia.
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TABLE 5. Multivariable Linear Regression Coefficients and 95% CIs for Sex, Age, and Education
Female Age (y) Education (y)
UDS Version 3 Neuropsychological Testa Coefﬁcient (95% CI) Coefﬁcient (95% CI) Coefﬁcient (95% CI)
MoCA, total score 0.35 (0.18, 0.52)** −0.08 (−0.08, −0.07)** 0.33 (0.30, 0.36)**
Craft Story 21 recall immed. verbatim 0.96 (0.51, 1.40)** −0.13 (−0.15, −0.11)** 0.41 (0.33, 0.48)**
Craft Story 21 recall immed. paraphrase 0.60 (0.33, 0.88)** −0.08 (−0.09, −0.07)** 0.28 (0.23, 0.33)**
Craft Story 21 recall delayed, verbatim 0.78 (0.33, 1.23)** −0.15 (−0.17, −0.13)** 0.43 (0.35, 0.51)**
Craft Story 21 recall delayed, paraphrase 0.52 (0.23, 0.81)** −0.10 (−0.11, −0.09)** 0.32 (0.27, 0.37)**
Benson complex ﬁgure copy, total score 0.04 (−0.05, 0.14) −0.01 (−0.02, −0.01)** 0.07 (0.06, 0.09)**
Benson complex ﬁgure recall, total score −0.47 (−0.67, −0.26)** −0.09 (−0.09, −0.08)** 0.16 (0.12, 0.19)**
Number span forward, total correct trials −0.29 (−0.45, −0.14)** −0.03 (−0.03, −0.02)** 0.15 (0.13, 0.18)**
Number span forward, longest span −0.16 (−0.25, −.0.07)** −0.01 (−0.02, −0.01)** 0.08 (0.07, 0.10)**
Number span backward, total correct trials −0.10 (−0.25, 0.05) −0.03 (−0.04, −0.03)** 0.17 (0.14, 0.20)**
Number span backward, longest span −0.06 (−0.15, 0.03) −0.02 (−0.02, −0.01)** 0.10 (0.08, 0.11)**
Multilingual naming test, total score −0.81 (−0.96, −0.66)** −0.03 (−0.04, −0.02)** 0.22 (0.19, 0.25)**
Verbal ﬂuency phonemic test, total correct F-words 0.54 (0.22, 0.85)** −0.05 (−0.07, −0.04)** 0.42 (0.36, 0.47)**
Verbal ﬂuency phonemic test, total correct L-words 0.63 (0.33, 0.92)** −0.05 (−0.07, −0.04)** 0.45 (0.40, 0.50)**
Verbal ﬂuency phonemic test, total correct F-words and L-words 1.12 (0.55, 1.69)** −0.09 (−0.12, −0.07)** 0.86 (0.76, 0.96)**
Category ﬂuency: animals, total score 0.35 (−0.02, 0.71) −0.15 (−0.16, −0.13)** 0.57 (0.50, 0.63)**
Category ﬂuency: vegetables, total score 2.49 (2.22, 2.77)** −0.08 (−0.10, −0.07)** 0.31 (0.26, 0.36)**
Trail making test part A, time (s) 0.03 (−0.72, 0.78) 0.45 (0.41, 0.48)** −0.73 (−0.86, −0.60)**
Trail making test part A, correct lines/time (s) −0.00 (−0.02, 0.02) −0.01 (−0.01, −0.01)** 0.02 (0.01, 0.02)**
Trail making test part B, time (s) 1.58 (−1.29, 4.45) 1.64 (1.50, 1.77)** −4.65 (−5.15, −4.15)**
Trail making test part B, correct lines/time (s) 0.00 (−0.01, 0.01) −0.01 (−0.01, −0.01)** 0.01 (0.01, 0.01)**
aHigher scores indicate better scores except for the trail making test parts A and B time in seconds.
**(Bold values) Statistically signiﬁcant at P< 0.01.
CI indicates conﬁdence interval; Immed, immediate; MoCA, Montreal Cognitive Assessment; UDS, Uniform Data Set.
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